A5102022459- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Glycosylation and Glycoproteins Research
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Research on Leishmaniasis Studies
- RNA Interference and Gene Delivery
- MicroRNA in disease regulation
- Ubiquitin and proteasome pathways
- Cancer Mechanisms and Therapy
- Hematopoietic Stem Cell Transplantation
- Hepatitis C virus research
- Renal Diseases and Glomerulopathies
- Hepatitis B Virus Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Circular RNAs in diseases
- Pediatric Urology and Nephrology Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Silymarin and Mushroom Poisoning
- Big Data and Digital Economy
- Eosinophilic Disorders and Syndromes
State Key Laboratory of Networking and Switching Technology
2024-2025
Switch
2025
Beijing University of Posts and Telecommunications
2024
Second Hospital of Shanxi Medical University
2016-2024
Shanxi Medical University
2016-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2014-2021
Institute of Hematology & Blood Diseases Hospital
2014-2021
XinHua Hospital
2020
Cornell University
2019
Peking University First Hospital
2013
Elevated inflammatory markers are associated with poor outcomes in various types of cancers; however, their clinical significance multiple myeloma (MM) have seldom been explored. This study investigated the prognostic relevance neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), and monocyte-to-lymphocyte (MLR) MM. Totally 559 MM patients were included this study. NLR, PLR MLR calculated from whole blood counts prior to therapy. Kaplan-Meier curves multivariate Cox...
Accumulating evidence indicates that intratumor heterogeneity is prevalent in multiple myeloma and a collection of multiple, genetically distinct subclones are present within the cell population. It not clear whether size clonal populations harboring unique cytogenetic abnormalities carry any additional prognostic value.We analyzed impact aberrations by fluorescence situ hybridization at different cutoff values cohort 333 patients with newly diagnosed 92 relapsed myeloma.We found nearly all...
Multiple myeloma (MM) is a complex disease with highly heterogeneous tumor biology, especially involving cytogenetic abnormalities.1 Consequently, MM patients display markedly diverse clinical characteristics, therapeutic responses, and outcomes.2,3 In this context, the international staging system (ISS) was developed to predict prognosis of in 2005,4 which later updated named revised ISS (R-ISS) 2015.5 Although R-ISS has widely been used as powerful tool guide daily practice till present,...
Single-cell analysis is of significant importance in delineating the exact phylogeny subclonal population and discovering subtle diversification. So far, studies intratumor heterogeneity clonal evolution multiple myeloma (MM) were largely focused on bulk tumor level. We performed quantitative multigene fluorescence situ hybridization (QM-FISH) 129 longitudinal samples 57 MM patients. All patients had newly diagnosed relapsed paired samples. An expanded cohort 188 underwent conventional FISH...
// Meirong Zang 1, * , Dehui Zou Zhen Yu 1 Fei Li 4 Shuhua Yi Xiaofei Ai Xiaoqi Qin Xiaoyan Feng 3 Wen Zhou 2 Yan Xu Zengjun Mu Hao Weiwei Sui Shuhui Deng Chirag Acharya Yaozhong Zhao Kun Ru Lugui Qiu Gang An State Key Laboratory of Experimental Hematology, Institute Hematology & Blood Diseases Hospital, Chinese Academy Medical Science Peking Union College, Tianjin, China Cancer Research Institute, Carcinogenesis Ministry Health and Invasion Education, Central South University, Changsha,...
Abstract Multiple myeloma (MM) is the second most prevalent hematologic malignancy. Although use of bortezomib (BTZ) significantly improves MM therapy, intrinsic and acquired drug resistance to BTZ remains a major clinical problem. In this study, we find that Cdc37, key co-chaperone Hsp90, downregulated in relapsed patients, especially after treatment, suggesting link between Cdc37 resistance. Suppression or inhibition Cdc37/Hsp90 association induces plasma cell dedifferentiation, quiescence...
The treatment of multiple myeloma (MM) with proteasome inhibitor (PI) bortezomib has significantly improved the survival patients MM. 26S targets unfolded protein response (UPR) by inhibiting degradation ubiquitinated paraprotein, subsequently leading to lethal accumulation paraprotein within endoplasmic reticulum. According secretory status monoclonal immunoglobulin, newly diagnosed MM (NDMM) is divided into measurable and unmeasurable disease, which includes oligosecretory, nonsecretory,...
To study the association between level of serum DKK1 and disease course multiple myeloma（MM）as well as myeloma bone disease.This enrolled 145 cases MM（including 79 newly diagnosed MM, 19 responded 47 relapsed or progressive MM） whose lytic were evaluated by conventional radiography, ELISA was used to detect concentration DKK1.Serum DKK-1 elevated in MM compared with normal donors［2 155（646-35 251）vs 1 487（646-2 577） ng/L, P=0.000］, those responded［1 136（431- 3 582） P=0.001］and...
To investigate the correlation of peripheral blood T lymphocyte subsets with overall survival (OS) and clinical baseline characteristics in mantle cell lymphoma (MCL).